argenx completes acquisition of Forte Biosciences for $77 per share

Reuters2026/08/27 12:50

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

argenx completed its acquisition of Forte Biosciences via a cash tender offer and subsequent merger.
Forte shareholders received USD 77 per share in cash, subject to applicable tax withholding.
At tender expiration on Aug. 26, 2026, 19,894,879 shares were tendered; ownership reached about 87.13% including argenx holdings.
Forte became a wholly owned subsidiary; its stock will no longer trade on Nasdaq.
Deal adds Forte’s FB102, an anti-CD122 antibody with clinical data in vitiligo and celiac disease, to argenx’s immunology pipeline.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608270850PRIMZONEFULLFEED1001259677) on August 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

argenx completes acquisition of Forte Biosciences for $77 per share

You may also like

Crypto prices